CALCA and migraine disorder: Notably, a proportion of patients with EM treated with CGRP(r) MoAbs had a complete response, i.e. no migraine episodes; at week 12 the proportion of complete responses was 16% for eptinezumab [18] and 35.5% for galcanezumab 120 mg [32], while at week 24 the proportion ranged from 11.5% to 15.6% for galcanezumab 120 mg, and from 13.8% to 14.6% for galcanezumab 240 mg [29, 30].